321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION

J.C-H Yang,T Kato,M-J Ahn,H Sakai,M Morise,Y-M Chen,J-Y Han,J Yang,J Zhao,J.L-C Huang,K Berghoff,R Bruns,H Vioix,G.P Otto,X Le,P.K Paik

doi:10.1016/j.annonc.2022.10.358

321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION

J.C-H Yang, T Kato + Show 14 more

https://doi.org/10.1016/j.annonc.2022.10.358

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: Nov 1, 2022

Affiliation: National Taiwan University, Sungkyunkwan University, Saitama Cancer Center, Taipei Veterans General Hospital, Guangdong Provincial People's Hospital, The University of Texas MD Anderson Cancer Center

#Tepotinib In Patients #MET Exon 14 + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Tepotinib, a MET TKI, is approved for METex14 skipping NSCLC in several Asian countries. In VISION (N=313; data cut-off: Feb 20, 2022), tepotinib demonstrated durable clinical activity with an objective response rate (ORR) of 50.8% and a median (m) duration of response (DOR) of 18.0 months. Tepotinib also showed promising intracranial activity in patients (pts) with brain metastases. We report data from all 106 Asian pts with METex14 skipping NSCLC enrolled in VISION.

Full Text